{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:45:03Z","timestamp":1792061103100,"version":"4.4.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.tjpad.2026.100685","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:17:49Z","timestamp":1792048669000},"page":"100685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updated Italian intersocietal recommendations for the appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8703-6940","authenticated-orcid":false,"given":"Alberto","family":"Benussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-4979","authenticated-orcid":false,"given":"Federica","family":"Agosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Agnello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba Rosa","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Altini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Antico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Basilico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5430-0947","authenticated-orcid":false,"given":"Giuseppe","family":"Bellelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Bottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bozzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Brignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"Cagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Francesca","family":"Calloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1003-3925","authenticated-orcid":false,"given":"Stefano F.","family":"Cappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9867-6054","authenticated-orcid":false,"given":"Filippo","family":"Caraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-1924","authenticated-orcid":false,"given":"Diego","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Ciaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirio","family":"Cocozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9400-6574","authenticated-orcid":false,"given":"Mirco","family":"Cosottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Falini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gaetani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Gandolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Gotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Logroscino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Marcello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-4044","authenticated-orcid":false,"given":"Camillo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Marrocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0729-5246","authenticated-orcid":false,"given":"Patrizia","family":"Mecocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7730-5836","authenticated-orcid":false,"given":"Enrico","family":"Mossello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-0547","authenticated-orcid":false,"given":"Lorenzo","family":"Palleschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-8530","authenticated-orcid":false,"given":"Leonardo","family":"Pantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Roccatagliata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Sorbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Spadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2188-3506","authenticated-orcid":false,"given":"Alessandra","family":"Splendiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tessitore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Zappal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2026.100685_bib0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2026.100685_bib0002","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2026.100685_bib0003","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimer Dis"},{"key":"10.1016\/j.tjpad.2026.100685_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimer Dis"},{"key":"10.1016\/j.tjpad.2026.100685_bib0005","first-page":"367","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"JALZ"},{"key":"10.1016\/j.tjpad.2026.100685_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/alz.71361","article-title":"Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer\u2019s disease: an update from the Alzheimer\u2019s Association ARIA workgroup","volume":"22","author":"van Etten","year":"2026","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100094","article-title":"Lecanemab for early Alzheimer\u2019s disease: appropriate use recommendations from the French federation of memory clinics","volume":"12","author":"Villain","year":"2025","journal-title":"J Prev Alzheimer Dis"},{"key":"10.1016\/j.tjpad.2026.100685_bib0008","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000545799","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer disease: intersocietal recommendations for their appropriate use in Switzerland","volume":"25","author":"Felbecker","year":"2025","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.tjpad.2026.100685_bib0009","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jnnp-2025-336597","article-title":"Lecanemab appropriate use recommendations for clinical practice in the UK","volume":"97","author":"Mummery","year":"2026","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tjpad.2026.100685_bib0010","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1007\/s10072-025-08576-y","article-title":"Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer\u2019s disease","volume":"46","author":"Benussi","year":"2025","journal-title":"Neurol Sci"},{"key":"10.1016\/j.tjpad.2026.100685_bib0011","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1007\/s10072-025-08577-x","article-title":"Monoclonal antibodies for early Alzheimer disease: a long road to discovery and marketing approval, a short timeline for health systems to organise services","volume":"46","author":"Cagnin","year":"2025","journal-title":"Neurolog Sci"},{"key":"10.1016\/j.tjpad.2026.100685_bib0014","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1474-4422(23)00447-7","article-title":"European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders","volume":"23","author":"Frisoni","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0015","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/alz.12798","article-title":"European consensus for the diagnosis of MCI and mild dementia: preparatory phase","volume":"19","author":"Festari","year":"2023","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0016","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s10072-025-08143-5","article-title":"Towards a new value-based scenario for the management of dementia in Italy: a SINdem delphi consensus study","volume":"46","author":"Marra","year":"2025","journal-title":"Neurolog Sci"},{"key":"10.1016\/j.tjpad.2026.100685_bib0017","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1007\/s10072-023-06885-8","article-title":"Assessing frailty at the centers for dementia and cognitive decline in Italy: potential implications for improving care of older people living with dementia","volume":"44","author":"Bellelli","year":"2023","journal-title":"Neurolog Sci"},{"key":"10.1016\/j.tjpad.2026.100685_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-30350-3","article-title":"Frailty detection among primary care older patients through the Primary Care Frailty Index (PC-FI)","volume":"13","author":"Vetrano","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjpad.2026.100685_bib0019","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4088\/JCP.tk16043ah5c","article-title":"Cognitive impairment in patients with depression: awareness, assessment, and management","volume":"78","author":"Culpepper","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.tjpad.2026.100685_bib0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3174\/ajnr.A8469","article-title":"Alzheimer Disease Anti-Amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities","volume":"46","author":"Cogswell","year":"2025","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0021","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2026.100685_bib0022","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-022-01056-x","article-title":"Italian adaptation of the Uniform Data Set neuropsychological test battery (I-UDSNB 1.0): development and normative data","volume":"14","author":"Conca","year":"2022","journal-title":"Alzheimer Res Ther"},{"key":"10.1016\/j.tjpad.2026.100685_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14338","article-title":"Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","author":"Rabinovici","year":"2025","journal-title":"Alzheimer Dement"},{"issue":"Suppl 1","key":"10.1016\/j.tjpad.2026.100685_bib0024","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1017\/S1041610297004870","article-title":"Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type","volume":"9","author":"Morris","year":"1997","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.tjpad.2026.100685_bib0025","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/23279095.2021.1952588","article-title":"Influence of education level on MMSE and MoCA scores of elderly inpatients","volume":"30","author":"Wu","year":"2023","journal-title":"Appl Neuropsychol Adult"},{"key":"10.1016\/j.tjpad.2026.100685_bib0026","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/09084282.2011.643962","article-title":"Is the Folstein\u2019s mini-mental test an aphasia test?","volume":"19","author":"Vigliecca","year":"2012","journal-title":"Appl Neuropsychol Adult"},{"key":"10.1016\/j.tjpad.2026.100685_bib0027","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/d41586-018-07535-2","article-title":"Statistical pitfalls of personalized medicine","volume":"563","author":"Senn","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.tjpad.2026.100685_bib0028","doi-asserted-by":"crossref","first-page":"1080.1","DOI":"10.1136\/bmj.332.7549.1080","article-title":"The cost of dichotomising continuous variables","volume":"332","author":"Altman","year":"2006","journal-title":"Br Med J"},{"key":"10.1016\/j.tjpad.2026.100685_bib0029","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad175","article-title":"Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer\u2019s disease","volume":"5","author":"Liu","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.tjpad.2026.100685_bib0030","first-page":"36","article-title":"Practical recommendations for monitoring response to amyloid-targeting treatments for early Alzheimer disease","volume":"5","author":"Brown","year":"2025","journal-title":"Pract Neurol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100226","article-title":"Bridging the gap: a conversion framework for CDR-SB and MoCA scores in Alzheimer\u2019s disease and related dementia","volume":"12","author":"Haji","year":"2025","journal-title":"J Prev Alzheimer Dis"},{"key":"10.1016\/j.tjpad.2026.100685_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14425","article-title":"Defining benefit: clinically and biologically meaningful outcomes in the next-generation Alzheimer\u2019s disease clinical care pathway","volume":"21","author":"Elhage","year":"2025","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0033","series-title":"Long-term benefit of lecanemab in patients with low baseline amyloid: estimation of time saved","author":"Dikson","year":"2025"},{"key":"10.1016\/j.tjpad.2026.100685_bib0034","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1093\/brain\/awv191","article-title":"The behavioural\/dysexecutive variant of Alzheimer\u2019s disease: clinical, neuroimaging and pathological features","volume":"138","author":"Ossenkoppele","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.tjpad.2026.100685_bib0035","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jalz.2017.01.014","article-title":"Consensus classification of posterior cortical atrophy","volume":"13","author":"Crutch","year":"2017","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0036","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamaneurol.2021.4417","article-title":"Research criteria for the behavioral variant of Alzheimer disease: a Systematic review and meta-analysis","volume":"79","author":"Ossenkoppele","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0037","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","article-title":"New insights into atypical Alzheimer\u2019s disease in the era of biomarkers","volume":"20","author":"Graff-Radford","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0038","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.3174\/ajnr.A7586","article-title":"Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice","volume":"43","author":"Cogswell","year":"2022","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0039","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","article-title":"The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study","volume":"21","author":"Charidimou","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0040","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2318-2-1","article-title":"Frailty, fitness and late-life mortality in relation to chronological and biological age","volume":"2","author":"Mitnitski","year":"2002","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.tjpad.2026.100685_bib0041","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.tjpad.2026.100685_bib0042","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-026-01966-0","article-title":"Are pre-frail and frail amyloid positive individuals eligible to Lecanemab? A cross-sectional analysis from the Cogfrail real-world cohort","volume":"18","author":"Bellelli","year":"2026","journal-title":"Alzheimer Res Ther"},{"key":"10.1016\/j.tjpad.2026.100685_bib0043","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s00259-021-05311-5","article-title":"A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images","volume":"48","author":"Bucci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.tjpad.2026.100685_bib0044","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70997","article-title":"Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies","volume":"21","author":"La Joie","year":"2025","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2025.103765","article-title":"A practical overview of the use of amyloid-PET centiloid values in clinical trials and research","volume":"46","author":"Iaccarino","year":"2025","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.tjpad.2026.100685_bib0046","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1002\/alz.14336","article-title":"Centiloid recommendations for clinical context-of-use from the AMYPAD consortium","volume":"20","author":"Collij","year":"2024","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0047","article-title":"Balancing benefit and risk in early Alzheimer\u2019s disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab","volume":"63","author":"Guizzaro","year":"2026","journal-title":"Lancet Region Health Eur"},{"key":"10.1016\/j.tjpad.2026.100685_bib0048","unstructured":"Lecanemab EU Risk Management Plan (Version 1.0) 2026."},{"key":"10.1016\/j.tjpad.2026.100685_bib0049","unstructured":"Donanemab EU Risk Management Plan (Version 0.9). 2025."},{"key":"10.1016\/j.tjpad.2026.100685_bib0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with Donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0051","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jamaneurol.2024.3937","article-title":"Amyloid-related imaging abnormalities in clinical trials of Gantenerumab in early Alzheimer disease","volume":"82","author":"Salloway","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0052","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimer Res Therapy"},{"key":"10.1016\/j.tjpad.2026.100685_bib0053","article-title":"Long-term safety and efficacy of lecanemab in early Alzheimer\u2019s disease: results from the clarity AD open-label extension study","volume":"21","author":"van Dyck","year":"2025","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0054","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimer Res Therapy"},{"key":"10.1016\/j.tjpad.2026.100685_bib0055","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-026-02015-6","article-title":"Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience","volume":"18","author":"Agosta","year":"2026","journal-title":"Alzheimer Res Ther"},{"key":"10.1016\/j.tjpad.2026.100685_bib0056","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1161\/STROKEAHA.113.002267","article-title":"Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo mri for detecting microbleeds","volume":"44","author":"Cheng","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.tjpad.2026.100685_bib0057","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3174\/ajnr.A1355","article-title":"MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength","volume":"30","author":"Nandigam","year":"2009","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0058","series-title":"Head-to-head comparison of SWI and T2*-weighted gradient echo MRI sequences to detect ARIA-H in the trailblazer-alz 6 trial of donanemab","author":"Svaldi","year":"2025"},{"key":"10.1016\/j.tjpad.2026.100685_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102981","article-title":"Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"114","author":"Shim","year":"2026","journal-title":"Age Res Rev"},{"key":"10.1016\/j.tjpad.2026.100685_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/alz70856_106489","article-title":"Association of occipital amyloid PET burden with ARIA-E: exploratory analyses in three clinical trials of Donanemab","volume":"21","author":"Kennedy","year":"2025","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0061","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","article-title":"Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform","volume":"31","author":"Palmqvist","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.tjpad.2026.100685_bib0062","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2026.100685_bib0063","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.tjpad.2026.100685_bib0064","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.tjpad.2026.100685_bib0065","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect Alzheimer disease in primary care and secondary care","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2026.100685_bib0066","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-026-08931-7","volume":"47","author":"Gaetani","year":"2026","journal-title":"Neurol Sci"},{"key":"10.1016\/j.tjpad.2026.100685_bib0067","article-title":"Alzheimer\u2019s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings","volume":"21","author":"Palmqvist","year":"2025","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0068","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70765","article-title":"Body mass index and blood volume influence plasma biomarkers and positron emission tomography classification in preclinical Alzheimer\u2019s disease","volume":"21","author":"Jacobs","year":"2025","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0069","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/alz.12787","article-title":"Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance","volume":"19","author":"Pichet Binette","year":"2023","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0070","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0071","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","article-title":"Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment","volume":"74","author":"Janelidze","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0072","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/alz.12316","article-title":"The Alzheimer\u2019s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0073","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-160722","article-title":"Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s disease","volume":"55","author":"Lewczuk","year":"2016","journal-title":"J Alzheimer Dis"},{"key":"10.1016\/j.tjpad.2026.100685_bib0074","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-022-01003-w","article-title":"The cerebrospinal fluid biomarker ratio A\u03b242\/40 identifies amyloid positron emission tomography positivity better than A\u03b242 alone in a heterogeneous memory clinic cohort","volume":"14","author":"Amft","year":"2022","journal-title":"Alzheimer Res Ther"},{"key":"10.1016\/j.tjpad.2026.100685_bib0075","first-page":"E1","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"9","author":"Johnson","year":"2013","journal-title":"JALZ"},{"key":"10.1016\/j.tjpad.2026.100685_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0077","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0078","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","article-title":"Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias","volume":"19","author":"Ch\u00e9telat","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0079","doi-asserted-by":"crossref","DOI":"10.1002\/alz.71064","article-title":"Defining patient-centered amyloid PET thresholds for the onset of tauopathy in Alzheimer\u2019s disease","volume":"22","author":"Zhu","year":"2026","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100685_bib0080","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaneurol.2025.3869","article-title":"Posttreatment amyloid levels and clinical outcomes following Donanemab for early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"82","author":"Lu","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100685_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100266","article-title":"The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema\/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6","volume":"12","author":"Wang","year":"2025","journal-title":"J Prev Alzheimer Dis"},{"key":"10.1016\/j.tjpad.2026.100685_bib0082","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-025-01811-w","article-title":"A novel biochemical analysis for ApoE4 quantification in plasma and discrimination of homozygous and heterozygous APOE \u03b54 carriers","volume":"17","author":"Rodr\u00edguez","year":"2025","journal-title":"Alzheimer Res Therapy"},{"key":"10.1016\/j.tjpad.2026.100685_bib0083","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14610","article-title":"Evaluation of two plasma-based proteotyping assays against APOE \u03b54 genotyping in a memory clinic setting: the Gothenburg H70 Clinical Studies","volume":"21","author":"Dittrich","year":"2025","journal-title":"Alzheimer Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726002086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726002086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:54:14Z","timestamp":1792058054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726002086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":81,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2274580726002086"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100685","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated Italian intersocietal recommendations for the appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100685","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100685"}}